Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data for early stage NSCLC

ABSTRACT: We identified a tumor signature of 5 genes that aggregates the 156 tumor and normal samples into the expected groups. We also identified a histology signature of 75 genes, which classifies the samples in the major histological subtypes of NSCLC. A prognostic signature of 17 genes showed the best association with post-surgery survival time. The performance of the signatures was validated using a patient cohort of similar size

ORGANISM(S): Homo sapiens

PROVIDER: GSE19188 | GEO | 2010/05/07

SECONDARY ACCESSION(S): PRJNA120673

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Expression data for early stage NSCLC

Project description:We identified a tumor signature of 5 genes that aggregates the 156 tumor and normal samples into the expected groups. We also identified a histology signature of 75 genes, which classifies the samples in the major histological subtypes of NSCLC. A prognostic signature of 17 genes showed the best association with post-surgery survival time. The performance of the signatures was validated using a patient cohort of similar size A genome-wide gene expression analysis was performed on a cohort of 91 patients. We used 91 tumor- and 65 adjacent normal lung tissue samples. We defined sets of predictor genes (probe sets) with the expression profiles. The power of predictor genes was evaluated using an independent cohort of 96 non-small cell lung cancer- and 6 normal lung samples

2010-05-28 | E-GEOD-19188 | biostudies-arrayexpress

Retrospective and prospective validation of a 33-gene signature to predict recurrence of lung cancer after surgery.

Project description:We developed a 33-gene signature that is strongly correlated to the time to recurrence in non-small cell lung cancer (NSCLC). The signature was validated retrospectively in 5 cohorts of 972 NSCLC patients and in one prospective study of 111 NSCLC Stage IA patients. In all cohorts, and all stages of the disease, the signature identified a rare, aggressive tumor type that had a high proportion of recurrence after surgery and a median survival of 35 months (95% C.I.: 19-58). This tumor type forms a separate cluster in an analysis of the expression of the 33 genes in patient tumors. The signature is associated with cellular processes required by rapidly growing and spreading tumors: cell migration and invasion, vascularization, and response to hypoxia. The signature also identifies patients with good prognosis (median survival 114 months, (95% C.I.: 85-160), and intermediate prognosis (median survival 61 months (95% C. I.: 50-73). The signature is quite robust and works on tumor samples archived in RNAlater, Tissue-Tek, or formalin-fixed and paraffin embedded. 156 samples -------------------------------- *** Submitter has not provided information such as time to recurrence. Thus, the data is incomplete.

2016-02-11 | E-GEOD-77803 | biostudies-arrayexpress

Expression profiling of CD24+ and CD24- tumor cells in Kras-driven NSCLC mouse model

Project description:Sustained tumor progression has been attributed to a distinct population of tumor-propagating cells (TPCs). To identify TPCs relevant to lung cancer pathogenesis, we investigated functional heterogeneity in tumor cells isolated from Kras-driven mouse models of non-small cell lung cancer (NSCLC). CD24+ITGB4+Notchhi cells are capable of propagating tumor growth in both a clonogenic and an orthotopic serial transplantation assay. While all four Notch receptors mark TPCs, Notch3 plays a non-redundant role in tumor cell propagation in two mouse model and in human NSCLC. The TPC population is enriched after chemotherapy and the gene signature of mouse TPCs correlates with poor prognosis in human NSCLC. The unique role of Notch3 in tumor propagation may provide a therapeutic target for NSCLC Highly purified primary tumor cells were FACS sorted based on expression of CD24. Samples were derived from six mice.

2013-07-08 | E-GEOD-46438 | biostudies-arrayexpress

Expression profiling of lung adenocarcinoma TPC tumor cells in Kras-driven NSCLC mouse model

Project description:Sustained tumor progression has been attributed to a distinct population of tumor-propagating cells (TPCs). To identify TPCs relevant to lung cancer pathogenesis, we investigated functional heterogeneity in tumor cells isolated from Kras-driven mouse models of non-small cell lung cancer (NSCLC). CD24+ITGB4+Notchhi cells are capable of propagating tumor growth in both a clonogenic and an orthotopic serial transplantation assay. While all four Notch receptors mark TPCs, Notch3 plays a non-redundant role in tumor cell propagation in two mouse model and in human NSCLC. The TPC population is enriched after chemotherapy and the gene signature of mouse TPCs correlates with poor prognosis in human NSCLC. The unique role of Notch3 in tumor propagation may provide a therapeutic target for NSCLC Primary lung adenocarcinoma tumor cells were FACS sorted based on expression of CD24, ITGB4 and Notch. TPC cells are defined by Cd24+ITGB4+ Notch(high), and the remainder tumor cells are non-TPC cells. Samples were derived from six mice.

2013-07-08 | E-GEOD-46439 | biostudies-arrayexpress

Transcriptome of human NSCLC tissues

Project description:RNA from patient samples was isolated to examine the TGFb pathway expression between matching pairs of tumor-free lung and NSCLC specimen RNA from patient samples was isolated to examine the TGFb pathway expression between matching pairs of tumor-free lung and NSCLC specimen

2016-05-18 | E-GEOD-74706 | biostudies-arrayexpress

Molecular classification of histological origin of NSCLC

Project description:Lung cancer is one of the most common malignant tumors in the world. The latest edition of WHO classifies lung cancer on the basis of histological morphology and molecular typing, which is a relatively complete pathological classification of lung cancer at present. However, in clinical practice, it is difficult to make accurate subtype classification of NSCLC only by using morphological structure and immunohistochemical characteristics, and the degree of coincidence with gene mutation and clinicopathological parameters is poor, which has limited guiding effect on clinical diagnosis and treatment. In this study, we proposed Molecular Pathological Classification Model of NSCLC Tissue Origin.

2022-04-01 | GSE168466 | GEO

Transcriptome of human NSCLC tissues

Project description:RNA from patient samples was isolated to examine the TGFb pathway expression between matching pairs of tumor-free lung and NSCLC specimen

2016-05-18 | GSE74706 | GEO

Gene expression profiles of NSCLC tumors

Project description:A custom microarray was used to measure the gene expression of NSCLC tumors. This represents a subset of samples which also have matched DNA copy number profiles from array CGH experiments 49 microdissected NSCLC tumor samples

2011-09-11 | E-GEOD-31799 | biostudies-arrayexpress

Expression profiling of lung adenocarcinoma TPC tumor cells in Kras-driven NSCLC mouse model

2013-07-08 | GSE46439 | GEO

Expression profiling of CD24+ and CD24- tumor cells in Kras-driven NSCLC mouse model

2013-07-08 | GSE46438 | GEO